[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-and-type-2-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-and-type-2-diabetes":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,80,103,129,164,195,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100609511","effects-of-hiit-vs-tre-on-type-2-diabetes-risk-100609511",false,"NCT07215533","Effects of HIIT vs. TRE on Type 2 Diabetes Risk","Differential Effects of HIIT vs. TRE on Type 2 Diabetes Risk in Youth and Younger Adults","Inclusion Criteria:\n\n* Adolescents (age 14-17 years old with sex- and race-specific BMI percentile ≥85th) and young adults with overweight and obesity (age 18 to 30 years old with BMI ≥25 kg\u002Fm2)\n\nExclusion Criteria:\n\n* Chronic medical conditions: heart disease, arrhythmias, diabetes, thyroid disease, bleeding disorder, history of pulmonary disease, hypertension, hepatorenal disease, musculoskeletal disorder, neuromuscular\u002Fneurological disease, autoimmune disease, cancer, peptic ulcers, anemia, or chronic infection (HIV).\n* Have taken any heart, pulmonary, thyroid, anti-hyperlipidemic, hypoglycemic, anti- hypertensive, endocrinologic (e.g., thyroid, insulin, etc.), emotional\u002Fpsychotropic (e.g., Prednisone, Ritalin, Adderall), neuromuscular\u002Fneurological, or androgenic medications (anabolic steroids).\n* Have a pacemaker.",true,"ALL","14 Years","30 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary aim of this randomized controlled trial is to examine the effects of a 4-week high-intensity interval training (HIIT) and time-restricted eating (TRE) intervention on cardiometabolic biomarkers in adolescents and young adults.",[28,29,30,31],"Obesity and Type 2 Diabetes","Metabolic Diseases","High-intensity Interval Training","Time-restricted Eating",[30,31,33,34,35,36],"Obesity","Type 2 Diabetes","Youth","Young Adults","RECRUITING","2025-10-08",{"date":40,"type":41},"2025-10-10","ACTUAL",{"date":43,"type":41},"2024-03-15",{"date":45,"type":22},"2025-12-30",{"name":47,"class":48},"Syracuse University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100576195","phase-4-effects-of-enavogliflozin-on-coronary-microvascular-and-cardiac-function-in-obesity-100576195","NCT06782139","Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity","Effects of ENavogliflozin on Coronary microVascular and Cardiac Function in Patients With obesitY (ENVY)","ENVY","Inclusion Criteria: The following criteria must be met for inclusion in the study:\n\n1. Obesity or Abdominal Obesity:\n\n   Body Mass Index (BMI) ≥ 25 kg\u002Fm², or Waist circumference: Male ≥ 90 cm, Female ≥ 85 cm.\n2. Diabetes:\n\nHemoglobin A1c ≥ 6.5%, or Fasting blood glucose ≥ 126 mg\u002FdL after 8 hours of fasting, or Currently on antidiabetic medication. Blood test results must be within 3 months prior to enrollment.\n\nOther inclusion criteria:\n\nAge between 20 and 79 years. Patients who have undergone coronary flow velocity reserve testing. For baseline echocardiography, left ventricular diastolic dysfunction will be evaluated structurally (LV dimension, LV mass index, LA size) and hemodynamically (Doppler data, left ventricular ejection fraction, strain data).\n\nExclusion Criteria:\n\n1. Left ventricular ejection fraction (LVEF) \\\u003C 50%\n2. History of coronary artery disease, or patients who have undergone coronary artery intervention or coronary artery bypass grafting.\n3. Patients with suspected obstructive coronary artery disease, including those with chest pain and positive stress test results (e.g., exercise treadmill test, dobutamine stress echocardiography, myocardial perfusion imaging).\n4. Second-degree or higher atrioventricular block, symptomatic bradycardia, sick sinus syndrome, or Wolff-Parkinson-White syndrome.\n5. Chronic kidney disease (GFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or end-stage renal disease on hemodialysis or peritoneal dialysis.\n6. Asthma, chronic obstructive pulmonary disease, or primary pulmonary hypertension.\n7. Moderate or severe valvular heart disease or congenital heart disease, or patients with a history of open-heart surgery.\n8. Active cancer within the last 5 years, or patients currently receiving chemotherapy.\n9. Vasculitis associated with autoimmune diseases, such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).\n10. Patients who cannot undergo exercise testing, such as treadmill or bicycle ergometer testing.\n11. Use of any other SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) within the past 6 months, or a known allergy to these drugs.\n12. Pregnant or breastfeeding women.\n13. Women planning pregnancy during the study period (or within 24 weeks from the start of the study, including the 12-week observation period).\n14. Acute urinary tract infection at the time of enrollment.","20 Years","79 Years",{"count":61,"type":22},30,[63],"PHASE4","The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.",[28],[67,33,68,69,70],"Sodium-Glucose Cotransporter 2 inhibitors","Diabetes","Coronary microvascular function","Epicardial adipose tissue","2025-08-25",{"date":73,"type":41},"2025-09-02",{"date":75,"type":41},"2025-01-20",{"date":77,"type":22},"2025-12-31",{"name":79,"class":48},"Korea University Anam Hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":49},"100579884","role-of-katp-channel-loss-in-type-2-diabetes-100579884","NCT06830096","Role of KATP Channel Loss in Type 2 Diabetes","Hyperglycemia Induced Hyperexcitability: A Novel Role for KATP in the Progression of Type 2 Diabetes","BC","Inclusion Criteria:\n\n* Lean-normoglycemic group (n=10): BMI ≥18.5 and \\\u003C25.0 kg\u002Fm², fasting plasma glucose concentration \\\u003C95 mg\u002Fdl, 2-hr oral glucose tolerance test plasma glucose concentration ≤140-mg\u002Fdl, and hemoglobin A1C (HbA1C) ≤5.6%.\n* Obesity-normoglycemic group (n=10): BMI ≥30 and \\\u003C50 kg\u002Fm², fasting plasma glucose concentration \\\u003C95 mg\u002Fdl, 2-hr oral glucose tolerance test plasma glucose concentration ≤140 mg\u002Fdl, and hemoglobin A1C (HbA1C) ≤5.6%.\n* Obesity-impaired fasting glucose group (n=10): BMI ≥30 and \\\u003C50 kg\u002Fm², fasting plasma glucose concentration 100-125 mg\u002Fdl, and 2-hr oral glucose tolerance test plasma glucose concentration \\\u003C200 mg\u002Fdl.\n* Obesity-type 2 diabetes group (n=10): BMI ≥30 and \\\u003C50 kg\u002Fm²; HbA1C 6.5-9.5%, fasting plasma glucose ≥126 mg\u002Fdl, 2-hr oral glucose tolerance test plasma glucose concentration ≥200 mg\u002Fdl and\u002For medical history of T2DM and currently using anti-diabetic medications.\n\nExclusion Criteria:\n\n* Diabetes therapy with insulin at \\>0.5 units\u002Fkg\u002Fday.\n* Any change in diabetes medication in previous 3 months.\n* Unstable weight (\\>2% change during the last 2 months before entering the study).\n* Evidence of significant organ system dysfunction or disease other than obesity and T2D.\n* Regular use of tobacco products.\n* Excessive consumption of alcohol (≥3 drinks\u002Fday for men and ≥2 drinks\u002Fday for women).\n* Use of medications that are known to affect the study outcome measures (e.g., steroids, non-statin lipid-lowering medications) or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study.\n* Anemia (Hemoglobin \\\u003C10.0 g\u002FdL).\n* Pregnant or breastfeeding.\n* Unable or unwilling to follow the study protocol or for any reason the research team believes the volunteer is not an appropriate candidate for this study, including non-compliance with screening appointments or previous medical visits.","18 Years","65 Years",{"count":21,"type":22},[25],"Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression.",[28],"2025-07-01",{"date":96,"type":41},"2025-07-04",{"date":98,"type":41},"2025-03-07",{"date":100,"type":22},"2026-07-01",{"name":102,"class":48},"Washington University School of Medicine",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":49},"100588561","adapting-and-assessing-the-feasibility-of-a-telehealth-diabetes-prevention-program-for-hispanic-adolescents-100588561","NCT06943001","Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents","Fit24+","Inclusion Criteria:\n\n* Self-report as Hispanic\n* obese, defined as body mass index percentile (BMI%) ≥ 95th percentile\n* ages of 12-16 years\n* owns his or her own cellphone\n\nExclusion Criteria:\n\n* Taking a medication (i.e. steroids) or diagnosed with a condition (i.e. sleep apnea) that influences activity, sleep, and\u002For cognition\n* Recent hospitalization or injury that prevents normal physical activity\n* Pregnant\n* Currently enrolled in an exercise program or currently using a personal activity monitoring device like Fitbit\n* Taking medications or diagnosed with a condition that influences activity, glucose metabolism, and\u002For cognition.","16 Years",{"count":21,"type":22},[25],"Hispanic adolescents are disproportionately burdened by type 2 diabetes (T2D). Social determinants of health (SDoH) serve as barriers to behavior change and participation in disease prevention efforts, especially among vulnerable adolescents. Telehealth is a potentially effective approach for delivering disease prevention programs as it addresses some SDoH like transportation, childcare needs, and parent work schedules. Unfortunately, there are no theory- or evidence-based telehealth diabetes prevention program for Hispanic adolescents. Therefore the purpose of this study is to adapt an evidence-based diabetes prevention program for delivery via telehealth and to test the feasibility of this study among Hispanic adolescents (12-16 years) with obesity.",[28],[116,117,118,119],"adolescents health","wearable sensors","user-centered design approac","T2D prevention","2025-04-23",{"date":122,"type":41},"2025-04-25",{"date":124,"type":41},"2025-04-12",{"date":126,"type":22},"2026-08-31",{"name":128,"class":48},"Baylor College of Medicine",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":148,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":49},"100584502","onestop-one-stop-telehealth-obesity-program-for-multidisciplinary-weight-management-and-related-comorbidities-100584502","NCT06890169","OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities","OneSTOP (One-Stop Telehealth Obesity Program): the Use of Telecare and Digital Platforms for Multidisciplinary Management of Weight Management and Related Comorbidities","OneSTOP","Inclusion Criteria:\n\n* Adults aged 21-70\n* Body mass index \\> 27.5 kg\u002Fm2\n* Waist circumference \\> 90 cm in men or 80 cm in women\n* Suboptimal control of type 2 diabetes (HbA1c \\> 6.5%) AND\u002FOR MASLD (as defined on radiological or histological evidence of hepatic steatosis in the absence of other chronic liver disease)\n\nExclusion Criteria:\n\n* Men who drink \\> 21 units\u002Fweek and women who drink \\> 14 units\u002Fweek of alcohol\n* Participants previously on weight-lowering medications (however if they are keen to participate, there will be a minimum wash-out period of 3 months before participation)\n* Illness with life expectancy of less than 6 months\n* Inability to comply with written instructions in English","21 Years","70 Years",{"count":140,"type":22},120,[25],"The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nResearchers will compare this model with the conventional standard of care of physical visit-based weight management program to see if this model is non-inferior to the standard of care for inducing weight loss, and if there is greater patient convenience with telehealth and more frequent self-monitoring, compliance with diet advice and exercise participation compared to standard of care.\n\nParticipants in the standard arm will attend 4 physical doctor and 4 physical dietician consultations over 26 weeks, where they will be provided with an individualized diet and exercise prescription to induce at least 5% weight loss.\n\nParticipants in the intervention arm will have the same number of consults over 26 weeks, of which at least 50% will be teleconsults, and will also be provided with an individualized diet and exercise prescription to induce at least 5% weight loss. In addition, they will be taught to use the EMPOWER app to upload weight, blood pressure and glucose, food and exercise records which will be reviewed at the consults. The app also delivers nudges to improve adherence to lifestyle modification.",[28,144,145,146,147],"NAFLD - Non-Alcoholic Fatty Liver Disease","Hypertension","Dyslipidaemia","Telemedicine",[149,150,151,152,153,154],"obesity","type 2 diabetes","masld","nafld","telecare","telemedicine","2025-03-17",{"date":157,"type":41},"2025-03-21",{"date":159,"type":22},"2025-05-01",{"date":161,"type":22},"2027-08-31",{"name":163,"class":48},"Changi General Hospital",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":16,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":49},"100573879","inflammations-impact-on-heart-disease-and-diabetes-100573879","NCT06752018","Inflammation's Impact on Heart Disease and Diabetes","Inflammation: a Key Contributor to Heart Disease and Diabetes?","INFO","Inclusion Criteria:\n\n* Individuals willing and able to give appropriate oral and written informed consent\n* Men and women over 18 years of age.\n* Correct body mass index (BMI) (Lean controls: 18.5-24.9 kg\u002Fm2. Obese gastric bypass patients: 35-50 kg\u002Fm2)\n\nExclusion Criteria:\n\n* The individual does not follow instructions given in the research study.\n* Pregnancy.\n* Significant gastrointestinal problems.\n* Use of tobacco.\n* The individual consumed alcohol within two days prior to the study visit\n* Active cancer within 5 years.\n* Use of dietary supplements that impact the inflammatory resolution process (e.g., fish oils), and the person is not willing to discontinue the use of the supplements 1 week prior to the visits.\n* Underlying cardiometabolic disease, or medication related to such disease (e.g., blood pressure medication, insulin to treat diabetes, etc.).\n* Underlying inflammatory disease, or medication related to such disease.\n* The individual states that they have increased bleeding tendency or are using anti-coagulant (blood-thinning) medication.\n* For obese patients only: The individual has lost more than 8% of his\u002Fher body weight since their clinical referral for surgery or has lost more than 3% of his\u002Fher body weight in the 4 months leading up to surgery.",{"count":173,"type":22},250,"OBSERVATIONAL","The goal of this observational study is to evaluate the inflammatory response associated with cardiometabolic diseases, and whether these can be reduced by ex vivo treatment with therapeutic agents. Briefly, the study involves two populations: healthy volunteers and severely obese patients undergoing weight-loss surgery. The main questions the study seeks to address are:\n\n1. To investigate if the therapeutic agents modulate the inflammatory response linked to obesity and cardiometabolic disease?\n2. What underlying factors contribute to variations in individual responses?\n\nResearchers will examine differences between healthy participants and those undergoing weight-loss surgery to assess the potential impact of weight loss on responsiveness and overall outcomes.\n\nParticipants will:\n\n* Undergo initial testing to evaluate their baseline response.\n* Provide samples during surgery for further analysis.\n* Participate in follow-up assessments to track changes over time.",[177,28,33,178,179],"Inflammation","Metabolic Syndrome","Anti-Inflammatory Agents",[181,182,183,184,185,177,179],"Disease","Overweight","overnutrition","body weight","Insulin resistance","2025-01-31",{"date":188,"type":41},"2025-02-03",{"date":190,"type":41},"2025-01-30",{"date":192,"type":22},"2030-12",{"name":194,"class":48},"University of Aarhus",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":4},"100575693","stem-cell-isolation-from-femoral-heads-post-total-hip-arthroplasty-100575693","NCT06775600","Stem Cell Isolation From Femoral Heads Post Total Hip Arthroplasty","Harvest of Human Bone Marrow-Derived Progenitor Cells During Total Hip Arthroplasty for Use in Regenerative Medicine Applications for Blood Vessel and Islet Regeneration.","Inclusion Criteria:\n\n* Must be 18+ years of age\n\nExclusion Criteria:\n\n* Diagnosis of bone cancers\n* Diagnosis of Rheumatoid arthritis\n* Diagnosis of hematopoietic conditions\n* Diagnosis of avascular necrosis of the hip\n* does not fall within BMI requirements for experimental groups\n* Cannot read and\u002For speak in english",{"count":61,"type":22},[25],"Femoral heads will be collected at University Hospital (London, ON, Canada) from individuals with type-2 diabetes, obesity, and no T2D\u002Fno obesity controls. The femoral head will be taken to the Robarts Research Institute (London, ON, Canada) for lineage-restricted progenitor cell expansion and analyses. There the femoral heads will be used to isolate three stem cell types - Multipotent Stromal Cells, Endothelial Colony Forming Cells, and Hematopoietic Progenitor Cells. The yield and cell surface markers expressed on these cells will be measured using flow cytometry. These cell types will then undergo further analyses of the secretome, tubule forming assays, vascular regenerative cell exhaustion assays, and will be transplanted into immune deficient mice with with femoral artery ligation. These experiments are to assess the differences in function and expression of these cell types between individuals with type-2 diabetes and\u002For obesity and\u002For healthy controls.",[28],[207,68,33,208],"Stem Cell","Regeneration","NOT_YET_RECRUITING","2025-01-14",{"date":212,"type":41},"2025-01-15",{"date":214,"type":22},"2025-02-01",{"date":216,"type":22},"2025-08-01",{"name":218,"class":48},"David Hess",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":16,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":225,"targetDuration":227,"studyType":174,"phases":4,"briefSummary":228,"conditions":229,"keywords":233,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":49},"100562121","regional-adipose-tissue-characteristics-in-type-ii-diabetes-100562121","NCT06599047","Regional Adipose Tissue Characteristics in Type II Diabetes","Inclusion Criteria:\n\n* Men, premenopausal and postmenopausal females between 18-65 years\n* Anticipating having bariatric surgery (participants with obesity) or general surgery in the abdominal area (normal weight participants) with a duration of less than 1.5 hours.\n* BMI 30 kg \u002F m2 (participants with obesity)\n* Weight Stable for a minimum of two months prior to the first pre-op visit\n\nExclusion Criteria:\n\n* Smoking\n* Renal impairment defined by creatinine clearance; 60 ml\u002Fminute\n* Uncontrolled hypothyroidism\n* No comorbidity other than diabetes type II Exceptions: controlled hypertension, hypothyroidism controlled, controlled dyslipidemia\n* Use prescribed medication that affect our outcomes E.g. Exceptions include metformin, DPP-4 inhibitors, inhibitors of the α-glucosidase, hypotensive with a stable dose for 3 months lipid lowering with a stable dose for 3 months.",{"count":226,"type":22},140,"1 Year","Fat tissue in different parts of the body has different characteristics. Several studies have associated abdominal fat to an increased risk for multiple metabolic diseases, such as type 2 diabetes and cardiovascular disease, compared with fat located under the skin at the hips and thighs. However, the investigators do not know how the abdominal fat causes or contributes to the development of these diseases or how the development of these disease may in turn cause or contribute to changes in the fat tissue. The general objective of this study is to understand these mechanisms.\n\nTo investigate these questions, the study will recruit 140 participants, both men and women aged 18-65 years. The participants will be divided into three groups: 40 people with obesity, 40 with diabetes, and 60 lean individuals. Participants will be recruited from patients at the CIUSSS du Nord-de-l'Île-de Montréal - Hôpital du Sacré-Coeur de Montréal who are awaiting bariatric or general abdominal surgery, as well as from the general population in the Montreal area.",[28,230,231,232],"Bariatric Patients Undergoing Bariatric Surgery","Adipose Tissue Dysfunction Type 2 Diabetes Mellitus Bariatric Surgery","Adipose Tissue Inflammation",[149,234,235,236,232],"Type 2 diabetes","Bariatric Surgery","Adipose Tissue Characterization","2024-10-20",{"date":239,"type":41},"2024-10-22",{"date":241,"type":41},"2016-05-01",{"date":243,"type":22},"2025-12",{"name":245,"class":48},"Concordia University, Montreal"]